A pivotal global study of AG-348 in adult patients with in pyruvate kinase (PK) deficiency
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs AG 348 (Primary)
- Indications Haemolytic anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Agios Pharmaceuticals
- 08 Aug 2017 According to an Agios Pharmaceuticals media release, the company expects to enroll aprox. 80 to 100 patient.
- 24 Jun 2017 According to an Agios Pharmaceuticals media release, the company expects to initiate the global pivotal development in the first half of 2018.
- 16 Feb 2017 According to Agios Pharmaceuticals media release, comapny expects to finalize study design in the third quarter of 2017.